Products for Research Use Only

ROC-0929

CAT: 0804-HY-145384-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145384-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ROC-0929 (compound 13a) is a potent and selective inhibitor of secreted phospholipases A2 (sPLA2s) with an IC50 of 80 nM, specially targeting hGX. ROC-0929 inhibits the phosphorylation of ERK1/2 and p-38. Secreted phospholipases A2 (sPLA2s) are a family of disulfide-rich, Ca2+-dependent enzymes that hydrolyze the sn-2 position of glycero-phospholipids to release a fatty acid and a lysophospholipid. ROC-0929 has the potential for researching inflammation related diseases[1].
CAS Number
1048660-43-0
UNSPSC
12352005
Target
Phospholipase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/roc-0929.html
Purity
99.62
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C(N)=O)C1=C(CC(C)C)N(CC2=CC=CC=C2)C3=CC=CC(OC(C)C(NS(=O)(C4=CC=CC=C4)=O)=O)=C31
Molecular Formula
C30H31N3O6S
Molecular Weight
561.65
References & Citations
[1]Oslund RC, et al. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J Med Chem. 2008;51 (15) :4708-4714. |[2]Hallstrand TS, et al. Endogenous secreted phospholipase A2 group X regulates cysteinyl leukotrienes synthesis by human eosinophils. J Allergy Clin Immunol. 2016;137 (1) :268-277.e8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products